Key summary points
The aim of this study was to determine the relationship between primary sarcopenia and SARC-F score, serum MMP9 (Matrix metalloproteinase), TIMP1 (Tissue inhibitor of metalloproteinase) levels, and MMP9/TIMP1 ratio in the geriatric patients.
AbstractSection FindingThe SARC-F and MMP9/TIMP1 ratio showed significant and similar diagnostic accuracy for sarcopenia.
AbstractSection MessageThe ability of SARC-F to screen similarly to more objective biomarkers such as the MMP9 / TIMP1 ratio for sarcopenia supports the use of the SARC-F questionnaire in daily practice.
Abstract
Purpose
The purpose of this study is to evaluate the relationship between serum MMP9 (Matrix metalloproteinase), TIMP1 (Tissue inhibitor of metalloproteinase) levels and MMP9/TIMP1 ratio and primary sarcopenia in geriatric patients, and compare the diagnostic accuracy of such biomarkers with that of the SARC-F score.
Methods
A total of 88 patients aged 65 years and older were assessed in the study. Comorbidities and geriatric syndromes were determined and patients with secondary sarcopenia were excluded. EWGSOP2 criteria were used as diagnostic criteria for sarcopenia and SARC-F questionnaire was used to find individuals at risk for sarcopenia. Serum MMP9 and TIMP1 levels were analyzed by ELISA method.
Results
SARC-F, serum MMP9 and MMP9/TIMP1 ratio were significantly higher in the group with sarcopenia compared to the group without sarcopenia (p = 0.001, p = 0.026 and p = 0.006, respectively). In univariate logistic regression analysis, while SARC-F score and MMP9/TIMP1 ratio were significant, MMP9, TIMP1, age and gender were not. In the multivariate logistic regression analysis of the SARC-F score and the MMP9/TIMP1 ratio, it was determined that both of them were associated with sarcopenia [Odds ratio (OR) 1.447 (95%) confidence interval (CI) 1.170–1.791, p = 0.001; OR 1.127, (95%) CI 1.016–1.249, p = 0.023, respectively]. ROC curve analysis showed that the area under ROC curve (AUC) of SARC-F and MMP9/TIMP1 was 0.703 (p = 0.001, %95 CI 0.594–0.812) and 0.670 (p = 0.006, %95 CI 0.557–0.783), respectively.
Conclusion
Although this study supports the use of SARC-F questionnaire in daily practice; if SARC-F can’t be applicable, the MMP9/TIMP1 ratio could be an alternative choice to the SARC-F.
Similar content being viewed by others
References
Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Singh MA (2002) Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. Am J Clin Nutr 76(2):473–481. https://doi.org/10.1093/ajcn/76.2.473
Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on defnition and diagnosis. Age Ageing 48(4):601. https://doi.org/10.1093/ageing/afz046
Paddon-Jones D, Short KR, Campbell WW, Volpi E, Wolfe RR (2008) Role of dietary protein in the sarcopenia of aging. Am J Clin Nutr 87(5):1562S-1566S. https://doi.org/10.1093/ajcn/87.5.1562S
Hao R, Guo H (2012) Anorexia, undernutrition, weight loss, sarcopenia, and cachexia of aging. Eur Rev Aging Phys Act 9(2):119–127
Morley JE, Kim MJ, Haren MT, Kevorkian R, Banks WA (2005) Frailty and the aging male. Aging Male 8(3–4):135–140. https://doi.org/10.1080/13685530500277232
Chen X, Li Y (2009) Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis. Cell Adh Migr 3(4):337–341. https://doi.org/10.4161/cam.3.4.9338
Alameddine HS, Morgan JE (2016) Matrix metalloproteinases and tissue inhibitor of metalloproteinases in inflammation and fibrosis of skeletal muscles. J Neuromuscul Dis 3(4):455–473. https://doi.org/10.3233/JND-160183
Alameddine HS (2012) Matrix metalloproteinases in skeletal muscles: friends or foes? Neurobiol Dis 48(3):508–518. https://doi.org/10.1016/j.nbd.2012.07.023
Chen Y, Wei X, Guo C, Jin H, Han Z, Han Y, Qiao T, Wu K, Fan D (2011) Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int J Cancer 129(7):1586–1598. https://doi.org/10.1002/ijc.25831
Niño ME, Serrano SE, Niño DC, McCosham DM, Cardenas ME, Villareal VP, Lopez M, Pazin-Filho A, Jaimes FA, Cunha F, Schulz R, Torres-Dueñas D (2017) TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: multivariate model. PLoS ONE 12(2):e0171191. https://doi.org/10.1371/journal.pone.0171191
Chen G, Ge D, Zhu B, Shi H, Ma Q (2020) Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury. J Int Med Res 48(4):300060520919592. https://doi.org/10.1177/0300060520919592
Uysal P, Uzun H (2019) Relationship between circulating serpina3g, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 and -2 with chronic obstructive pulmonary disease severity. Biomolecules 9(2):62. https://doi.org/10.3390/biom9020062.PMID:30781876;PMCID:PMC6406460
Anaya-Segura MA, García-Martínez FA, Montes-Almanza LA, Díaz BG, Avila-Ramírez G, Alvarez-Maya I, Coral-Vazquez RM, Mondragón-Terán P, Escobar-Cedillo RE, García-Calderón N, Vazquez-Cardenas NA, García S, López-Hernandez LB (2015) Non-invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules 20(6):11154–11172. https://doi.org/10.3390/molecules200611154
Kieseier BC, Schneider C, Clements JM, Gearing AJ, Gold R, Toyka KV, Hartung HP (2001) Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 124(Pt 2):341–351. https://doi.org/10.1093/brain/124.2.341
Malmstrom TK, Morley JE (2013) Sarcopenia: the target population. J Frailty Aging 2(1):55–56. https://doi.org/10.14283/jfa.2013.8
Sánchez-Rodríguez D, Marco E, Dávalos-Yerovi V, López-Escobar J, Messaggi-Sartor M, Barrera C, Ronquillo-Moreno N, Vázquez-Ibar O, Calle A, Inzitari M, Piotrowicz K, Duran X, Escalada F, Muniesa JM, Duarte E (2019) Translation and validation of the Spanish version of the SARC-F questionnaire to assess sarcopenia in older people. J Nutr Health Aging 23(6):518–524. https://doi.org/10.1007/s12603-019-1204-z
Zasadzka E, Pieczyńska A, Trzmiel T, Pawlaczyk M (2020) Polish translation and validation of the SARC-F tool for the assessment of sarcopenia. Clin Interv Aging 22(15):567–574. https://doi.org/10.2147/CIA.S245074
Kim S, Kim M, Won CW (2018) Validation of the Korean version of the SARC-F questionnaire to assess sarcopenia: Korean frailty and aging cohort study. J Am Med Dir Assoc 19(1):40-45.e1. https://doi.org/10.1016/j.jamda.2017.07.006
Gade J, Beck AM, Rønholt F, Andersen HE, Munk T, Vinther A (2020) Validation of the Danish SARC-F in hospitalized, geriatric medical patients. J Nutr Health Aging 24(10):1120–1127. https://doi.org/10.1007/s12603-020-1453-x
Bahat G, Yilmaz O, Kılıç C, Oren MM, Karan MA (2018) Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging 22(8):898–903. https://doi.org/10.1007/s12603-018-1067-8
Kurita N, Wakita T, Kamitani T, Wada O, Mizuno K (2019) SARC-F validation and SARC-F+EBM derivation in musculoskeletal disease: the SPSS-OK study. J Nutr Health Aging 23(8):732–738. https://doi.org/10.1007/s12603-019-1222-x
da Luz MCL, Pinho CPS, Bezerra GKA, da de Lemos CCM, da Silva DA, Cabral PC (2021) SARC-F and SARC-CalF in screening for sarcopenia in older adults with Parkinson’s disease. Exp Gerontol 144:111183. https://doi.org/10.1016/j.exger.2020.111183
Mazocco L, Chagas P, Barbosa-Silva TG, Gonzalez MC, Schwanke CHA (2020) Accuracy of SARC-F and SARC-CalF for sarcopenia screening in older women from southern Brazil. Nutrition 79–80:110955. https://doi.org/10.1016/j.nut.2020.110955
Woo J, Yu R, Leung J (2018) A 3-Item SARC-F. J Am Med Dir Assoc 19(3):223–228. https://doi.org/10.1016/j.jamda.2017.09.006
Funding
This work was supported by The Research Fund of Istanbul University-Cerrahpasa (Project Number 33498).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Statement of human and animal rights
The study has been approved by the ethics committee of the Cerrahpasa Medical Faculty.
Informed consent
Written informed consent was obtained from each subject.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Suzan, V., Yavuzer, H., Bag Soytas, R. et al. The relationship between primary sarcopenia and SARC-F, serum MMP9, TIMP1 levels, and MMP9/TIMP1 ratio in the geriatric patients. Eur Geriatr Med 12, 1229–1235 (2021). https://doi.org/10.1007/s41999-021-00519-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s41999-021-00519-y